| Mn Veterans Home - Luverne | |
| 1300 North Kniss, Po Box 539, Luverne, Minnesota 56156 | |
| (507) 283-6200 | |
| Name | Mn Veterans Home - Luverne |
|---|---|
| Location | 1300 North Kniss, Po Box 539, Luverne, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 85 |
| Occupancy Rate | 83.29% |
| Medicare ID (CCN) | 245631 |
| Legal Business Name | State Of Minnesota-minnesota Management And Budget |
| Ownership Type | Government - State |
| NPI Number | 1568735090 |
| Organization Name | STATE OF MINNESOTA-MINNESOTA MANAGEMENT AND BUDGET |
| Doing Business As | MINNESOTA VETERANS HOME - LUVERNE |
| Address | 1300 N Kniss Ave, Luverne, MN 56156 |
| Phone Number | 507-283-6200 |
News Archive
LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim's® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
Sherpa Clinical Packaging, a privately held provider of Clinical Trial Material management services, hosted a ribbon cutting ceremony today to mark the opening of its newly constructed state-of-the-art, CGMP production facility in San Diego, CA.
A recent study published in the Journal Emerging Microbes and Infections has highlighted the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant with mutations in the membrane protein-encoding gene. Two potential mutations, M:I82T and M:V70L, have been identified within the transmembrane helices, which are expected to improve viral fitness by modulating glucose uptake during replication.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).
Leading medical organisations are due to speak at the first ever Medical Support Operations Conference, a three-day event providing a unique opportunity to network with industry leaders, NGOs and military end users' such as Humanity First and the European External Action Service.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim's® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
Sherpa Clinical Packaging, a privately held provider of Clinical Trial Material management services, hosted a ribbon cutting ceremony today to mark the opening of its newly constructed state-of-the-art, CGMP production facility in San Diego, CA.
A recent study published in the Journal Emerging Microbes and Infections has highlighted the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant with mutations in the membrane protein-encoding gene. Two potential mutations, M:I82T and M:V70L, have been identified within the transmembrane helices, which are expected to improve viral fitness by modulating glucose uptake during replication.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).
Leading medical organisations are due to speak at the first ever Medical Support Operations Conference, a three-day event providing a unique opportunity to network with industry leaders, NGOs and military end users' such as Humanity First and the European External Action Service.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.15 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.84 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.82 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.39 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.77 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.06 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.37 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 17.53 | 14.2 |